ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AXDX Accelerate Diagnostics Inc

0.9248
-0.0171 (-1.82%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Accelerate Diagnostics Inc NASDAQ:AXDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0171 -1.82% 0.9248 0.7111 1.48 0.98 0.9199 0.94 26,878 05:00:07

Accelerate Diagnostics scheduled call to review 2022 third quarter results

24/10/2022 3:02pm

PR Newswire (US)


Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Accelerate Diagnostics Charts.

TUCSON, Ariz., Oct. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter results.

Accelerate Diagnostics, Inc. (PRNewsfoto/Accelerate Diagnostics)

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 5844198. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 7894082 until December 5, 2022.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antimicrobial resistance and sepsis. The Accelerate Pheno® system is designed to reduce the time clinicians must wait to determine the most optimal antibiotic therapy for bacteremic patients. These diagnostic systems are designed to serve clinical laboratories with automated solutions to expedite time to identification and antimicrobial susceptibility test (AST) results directly from positive blood culture samples. Multiple external studies have proven that Accelerate solutions deliver results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-third-quarter-results-301657334.html

SOURCE Accelerate Diagnostics, Inc.

Copyright 2022 PR Newswire

1 Year Accelerate Diagnostics Chart

1 Year Accelerate Diagnostics Chart

1 Month Accelerate Diagnostics Chart

1 Month Accelerate Diagnostics Chart

Your Recent History

Delayed Upgrade Clock